Starting from this trial, a still recruiting large-scale study called ZEUS will compare ziltivekimab with placebo in subjects with chronic kidney disease and elevated hsCRP to study if the reduction of IL-6 decreases the cardiovascular event rates (ClinicalTrials.gov Identifier: NCT05021835). This evidence concerns the gene IL6 and chronic kidney disease.